SeekInCureTM
The first-in-class blood-based pan-cancer recurrence monitoring test
SeekInCureTM is applied to monitoring cancer recurrence and risk evaluation for post-op cancer patients. By monitoring the variation of cancer genome in cell-free DNA (cfDNA) of post-op cancer patients continually, combined with plasma protein markers, equipping big data and artificial intelligence, it generates cancer recurrence index (CRI) .
Specifications
◉ Indicated subjects: post-surgery cancer patients
◉ Sample requirement: 8ml peripheral blood
◉ Result readout: CRI (cancer recurrence index)
◉ Turnaround time (TAT): 10 working days
Sampling time
How it works
Customer order
Customers can place orders through SeekIn official website or local agents
Blood-draw
8 ml venous peripheral blood collected in cell-free DNA BCT and can be stably stored at room temperature for 7 days
Testing
Detection by Roche cobas e411 instrument + high-throughput sequencing platform
Reporting
The test results will be ready in about 10 workdays after your blood draw arrived at central lab
